IKZF2 is abundantlypresent in leukemia stem cells and theirloss leads to a reversal of immune-suppressive activity convertingTregs into effector T cells. Degradationof IKZF2 in Treg cells as well as other T cells could potentiallyenhance the antitumor immune response, making IKZF2 a promising candidatefor cancer immunotherapy. The gene discussed is IKZF2; the disease is leukemia.